These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36201220)

  • 1. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?-Reply.
    Suurmeijer JA; Besselink MG; van Laarhoven HWM
    JAMA Oncol; 2022 Dec; 8(12):1851-1852. PubMed ID: 36201220
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?
    Reni M; Macchini M; Orsi G
    JAMA Oncol; 2022 Dec; 8(12):1851. PubMed ID: 36201191
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
    Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2469-2470. PubMed ID: 36567385
    [No Abstract]   [Full Text] [Related]  

  • 6. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
    Paniccia A; Zureikat A
    Ann Surg Oncol; 2023 Jun; 30(6):3184-3185. PubMed ID: 36847954
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
    Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
    Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
    Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
    Suto H; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Kumamoto K; Suzuki Y; Okano K
    HPB (Oxford); 2023 Jan; 25(1):136-145. PubMed ID: 36307256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
    Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
    Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria?
    Takaori K
    Pancreatology; 2018 Jan; 18(1):1. PubMed ID: 29389525
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
    Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
    Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant treatment concepts for borderline-resectable adenocarcinoma of the pancreas].
    Roth S; Schneider M
    Chirurgie (Heidelb); 2022 Oct; 93(10):995-996. PubMed ID: 36063204
    [No Abstract]   [Full Text] [Related]  

  • 19. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
    Isaji S; Mizuno S; Windsor JA; Bassi C; Fernández-Del Castillo C; Hackert T; Hayasaki A; Katz MHG; Kim SW; Kishiwada M; Kitagawa H; Michalski CW; Wolfgang CL
    Pancreatology; 2018 Jan; 18(1):2-11. PubMed ID: 29191513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
    Schwarz L; Katz MH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.